UAE approves Rinvoq for vitiligo in patients 12+ as first oral systemic option

The Emirates Drug Establishment (EDE) has approved RINVOQ (upadacitinib) for non-segmental vitiligo in adults and adolescents aged 12 years and older who need systemic therapy, making the UAE the first country to approve this expanded use, according to WAM and Qazinform.

The decision matters first to dermatology clinics and medical directors in Dubai. They now have a once-daily oral option for selected patients whose disease is too extensive, active or impractical for topical-only care. It also matters to CFOs and insurers because UAE retail references for existing RINVOQ 15mg 30-tablet packs sit around AED 5,789 to AED 6,094 on pharmacy and drug-index listings checked on 20 August 2026. Clinics should verify the official reimbursable price through the EDE or Ministry of Health and Prevention (MOHAP) medicine price-list service before quoting patients.

What EDE has approved

The approval covers non-segmental vitiligo, the common bilateral form of the condition, and only patients who meet the approved medical criteria for systemic treatment. RINVOQ is a Janus kinase inhibitor. It acts through the bloodstream and is taken once daily, which changes the workflow for patients who have been using topical medicines, phototherapy or laser-based services.

“The medicine is taken orally once a day.” — Emirates Drug Establishment, WAM statement, 17 August 2026

The clinical evidence behind the indication is the Viti-Up Phase 3 programme. AbbVie said in October 2025 that two Phase 3 studies met co-primary endpoints at week 48. Dermatology Times reported that the trials enrolled 614 participants aged 12 and older across 90 global sites, with upadacitinib 15mg once daily compared with placebo.

• Eligibility: adults and adolescents aged 12+ with non-segmental vitiligo requiring systemic therapy.
• Dosing route: oral tablet, once daily, under specialist prescription.
• Evidence timeframe: primary assessment at 48 weeks in the Viti-Up studies.
• Current UAE action: verify availability, official price and payer approval before initiation.

Dubai clinics need a prescribing pathway

For Dubai providers, the practical regulator remains the Dubai Health Authority (DHA) for facility licensing, professional licensing and local clinical governance. EDE approval allows the medicine to be used for the new indication, but DHA-licensed clinics still need internal protocols for diagnosis, baseline assessment, consent and follow-up. Patients should be told that the approval is for a defined subgroup, rather than all white skin patches or all vitiligo cases.

Medical directors should build a short checklist before prescribing. It should cover disease type, age, prior topical or device-based treatment, immune-risk history, infection screening needs, current medicines and documentation of why systemic therapy is appropriate. RINVOQ affects immune signalling, so the prescribing note should be stronger than a cosmetic-treatment record.

The insurance question is unresolved at the patient level. Dubai clinics should check benefits with the insurer shown on the card, including Sukoon where relevant. Abu Dhabi providers should check Daman and Thiqa pathways where those schemes apply. A prior-authorisation request is likely for many patients because published UAE retail references for existing packs are above AED 5,700 per 30 tablets, and vitiligo coverage may depend on medical necessity, severity and policy exclusions.

Abu Dhabi and northern emirates

In Abu Dhabi and Al Ain, the operating regulator is the Department of Health Abu Dhabi (DOH). DOH-licensed dermatology services should expect the same clinical question but a different payer process, particularly for Daman and Thiqa members. For Sharjah, Ajman, Ras Al Khaimah, Fujairah and Umm Al Quwain, MOHAP is the relevant health regulator for many private-sector licensing and professional matters, while EDE remains the federal medicine regulator.

The patient demand signal is clear enough for clinics to prepare. Vitiligo affects an estimated 0.5% to 1% of the global population, according to The National’s report on the UAE approval. In a UAE clinic, the addressable group will be smaller: patients aged 12 or older, diagnosed with non-segmental disease, assessed as needing systemic therapy, and cleared for a JAK inhibitor after specialist review.

Operators should avoid advertising the treatment as a cure. The stronger commercial move is operational: publish a vitiligo assessment pathway, train call-centre staff to book these cases with dermatology rather than aesthetics, and prepare insurer templates that explain age, diagnosis, body areas affected, prior treatment and systemic-therapy rationale. Patients looking for licensed dermatology providers can start with the UAE Open Healthcare Directory, then confirm the provider’s DHA, DOH or MOHAP licence before booking.